Patrick Andre, Ph.D., is a pioneer in integrin biology and drug discovery who brings to Pliant 15 years of experience in target identification, validation and drug development. Prior to Pliant, Dr. Andre served as Principal Scientist at Merck Sharp & Dohme Corp., a subsidiary of Merck, where he worked in the Cardio Metabolic Department. There, he led programs from target identification through lead identification and optimization, and served as therapeutic area representative for a marketed drug. Prior to Merck, Dr. Andre held positions of increasing responsibility at Portola Pharmaceuticals for nine years, most recently as Senior Director, where he developed novel assays and performed mechanistic studies for antiplatelet, anticoagulant and anti-inflammatory agents. Dr. Andre has published more than 40 articles in top-tier peer-reviewed journals and holds more than 15 patents.
Dr. Andre holds a Ph.D. in molecular biology from Paris VII University and completed his postdoctoral research at Harvard Medical School.